INTRODUCTION
Candidiasis, which is caused by Candida albicans, is the most common Candida infection found in immunocompromised patients, particularly in human immunodeficiency virus (HIV)-infected patients (Pohan, 2006; de Repentigny et al., 2004; Wingeter et al., 2007) . The antifungal fluconazole has been widely used as first-line therapy for antifungal prophylaxis or empirical treatment for Candida infections (Pappas et al., 2009) . This extensive use of fluconazole has the potential to lead to emergence of resistant Candida strains, which have been detected in many countries (Orrù et al., 2008; Morio et al., 2010; Perea et al., 2001) . Four molecular mechanisms have been reported to confer fluconazole resistance in C. albicans (Perea et al., 2001; Marichal et al., 1999; White et al., 2002) . The first is the reduction of intracellular fluconazole due to the overexpression of genes encoding efflux transporters belonging to the ATP-binding cassette superfamily (CDR1 and CDR2) or major facilitator superfamily (MDR1). A second mechanism is mutation of the ERG11 gene encoding lanosterol 14a-demethylase (CYP51), the primary target of fluconazole. The mutation causes a structural change in lanosterol 14a-demethylase; consequently, it changes the affinity of fluconazole for this enzyme. The third is an intracellular concentration of fluconazole insufficient to inhibit the function of CYP51 due to overexpression of the ERG11 gene. The last mechanism involves alterations in the ergosterol biosynthetic pathway.
In clinical isolates, several resistance mechanisms often act synergistically (White et al., 2002; Wang et al., 2009; Sanglard & Odds, 2002) . One study reported that 85 % of isolates overexpressed efflux pumps, 65 % of isolates had mutations in ERG11, and 35 % of isolates overexpressed ERG11 (Perea et al., 2001) . Another study showed that most of the amino acid changes in CYP51 were clustered into three hotspot regions: aa 105-165, 266-287 and 405-488 (Marichal et al., 1999) . Of these amino acid changes, A61V, Y132H, K143R, S405F, F449S, G464S, R467K and I471T were associated with fluconazole resistance (Orrù et al., 2008; Morio et al., 2010; Perea et al., 2001; Marichal et al., 1999; White et al., 2002) .
There are no data available about the molecular mechanism of fluconazole resistance in C. albicans isolated in Indonesia. However, fluconazole is the standard treatment for oropharyngeal candidiasis (OPC), which is the third most common opportunistic infection in HIV/AIDS (acquired immunodeficiency syndrome) patients in Indonesia. Data about the molecular mechanisms of fluconazole resistance in C. albicans were therefore required for treatment guidelines and the utilization of laboratory testing for early detection. The molecular mechanisms of fluconazole resistance (mutation and overexpression of the ERG11 gene and overexpression of the CDR1, CDR2 and MDR1 genes) in C. albicans isolated from the oropharynx of HIV-infected patients in Indonesia were analysed in this study.
METHODS
Isolation and culture. C. albicans isolates were obtained from 108 HIV-infected patients in the Cipto Mangunkusumo Hospital, Jakarta, Indonesia from May 2009 to September 2010. All patients were included in this study except those exposed to antifungals up to 1 month previously. This study was approved by the Ethical Committee of the hospital and Faculty of Medicine, University of Indonesia (no. 162/PT02.FK/ETIK/2009) and all patients gave their written consent before enrolment in the study. C. albicans was isolated from the oral cavity by the concentrated oral rinse technique, i.e. an oral rinse procedure using 10 ml sterile PBS (0.1 M, pH 7.2), which was held in the mouth for 1 min, then collected in a sterile container. Each rinse was centrifuged (3000 g; 15 min), 7.5 ml of the supernatant was removed and 2.5 ml of the deposit was used for further testing. The presence of any budding yeast and pseudohyphae was detected by Gram staining. To test for growth, a portion (100 ml) of the concentrate was inoculated onto mycobiotic agar plates containing chloramphenicol and cycloheximide, and suspected Candida colonies were subcultured onto plates containing Sabouraud dextrose agar, which were incubated at 35 uC for 48 h.
Identification and susceptibility testing. Yeast identification was conducted using the commercial API 20C AUX method (bioMér-ieux). After incubation at 30 uC for 24-48 h, the results were read visually and interpreted using the API database (Agha et al., 2012 ). The susceptibility was tested using the commercial ATB Fungus 3 method (ATBF3; bioMérieux RNA extraction. Azole-resistant C. albicans isolates in ATBF3 medium containing antifungal drugs were immediately propagated in physiological saline with constant shaking at room temperature until 1 McFarland unit was reached. The suspension (1 ml) was centrifuged at 500 g at 4 uC for 5 min, and the pellet was stored at 230 uC until use. Total RNA was extracted using the Pure Link RNA Mini kit (Invitrogen) with PureLink DNase (Invitrogen). The quality of RNA was checked using real-time PCR (Fast Start SYBR Green Master kit; Roche). The eluate was stored at 280 uC for not more than 1 week before use.
DNA extraction. A single colony of azole-resistant C. albicans was propagated in physiological saline with constant shaking at room temperature until 1 McFarland unit was reached. Aliquots of the suspension (1 ml) were harvested by centrifugation at 500 g for 5 min at 4 uC. The supernatant was removed and the deposit was stored at 230 uC until it was used for DNA extraction. Total cellular DNA and RNA were extracted using the Pure Link RNA Mini kit (Invitrogen) without adding DNase. The eluate was stored at 230 uC until use.
One-step real-time reverse transcriptase PCR (rRT-PCR) for mRNA overexpression analysis. Primers for ERG11, CDR1, CDR2, MDR1 and the housekeeping gene (18S rRNA) were used as reported previously (Chen et al., 2010) . One-step rRT-PCR was performed using 25 ml of the following reaction mixture: 1| reaction mix, 0.6 mM each primer, 2 ml Superscript III Platinum SYBR Green One-
Step qRT-PCR (Invitrogen) and 12.5 ml RNA. The reaction was performed under the following conditions (IQ5; Bio-Rad): 50 uC for 5 min; 95 uC for 10 min; 32 cycles of 95 uC for 10 s, 57 uC for 30 s, and 72 uC for 1 min. When the amplification was complete, 8 ml amplification product was separated using 0.8 % agarose gel electrophoresis with the Fermentas 100 bp molecular mass standard. The expression levels of ERG11, CDR1, CDR2 and MDR1 were calculated by the 2 2DDC t method, where C t is the mean of the number of threshold cycles from two independent experiments. The housekeeping (18S rRNA) gene was used to normalize the fold change in gene expression.
Amplification of the full-length ERG11 gene. The full-length ERG11 gene was amplified by using specific primers designed by Primer Designer Version 2, Scientific & Educational Software (Table 1) . Primers for sequencing were composed of eight overlapping primers, in order to read the sense and antisense DNA sequences. ERG11 gene reference sequences used for primer design were downloaded from GenBank with the accession number GQ202082. The Pfu DNA Polymerase kit (Genecraft) was used for PCR amplification. PCR was performed in a volume of 50 ml with the following components: 6 ml 10| Pfu buffer with MgSO 4 ; 1.2 ml 10 mM dNTP mix; 1.8 ml 10 mM each primer CA-F and CA-R; 0.6 ml enzyme (Pfu DNA polymerase); 42.6 ml water (PCR grade); 6 ml DNA diluted 1:10 from the final dilution. The reaction was performed under the following conditions (IQ5; Bio-Rad): 95 uC for 2 min; 38 cycles of 95 uC for 30 s, 56 uC for 30 s and 72 uC for 2 min; and 72 uC for 10 min. The PCR products were analysed on a 0.8 % agarose gel with the Fermentas 1 kb molecular mass standard. A specific 1587 bp DNA (ERG11 gene) fragment was purified from the gel using the GeneJET PCR Purification kit (Genecraft).
DNA sequencing and overlapping DNA sequence editing. The purified DNA was subjected to DNA sequencing reactions by using eight overlapping primers (Table 1) . Sequencing reactions were performed with BigDye Terminator Cycle Sequencing using 8 ml DNA template (10-40 ng) and 1 ml primers (10 mM). PCR was performed on 20 ml mixture for 25 cycles of 96 uC for 10 s, 53 uC for 5 s, 60 uC for 4 min and 4 uC for 10 min. After the reaction, the PCR product was purified with ethanol, EDTA and sodium acetate. The DNA pellets were dissolved in Hi-Di formamide for DNA sequencing. The DNA sequences were derived using an automated sequencer (3130/ Genetic Analyzers; Applied Biosystems). Overlapping DNA sequence editing was performed by using SeqScape v2.7 (Applied Biosystems).
RESULTS

Identification and susceptibility testing
The most common OPC aetiology found in HIV-infected patients in the Cipto Mangunkusumo Hospital, Jakarta, Indonesia, was C. albicans (85.2 %), whereas 5.5 % were Candida non-albicans, including C. dubliniensis, C. guillermondii, C. famata, C. tropicalis and C. parapsilosis. Of 92 C. albicans isolates, 17 (18.5 %) were resistant to azole antifungals and 12 (13.0 %) were resistant to fluconazole, as seen in Table 2 . Of the 17 C. albicans isolates resistant to azoles, three isolates (17.6 %) were single-resistant to fluconazole, two isolates (11.8 %) were single-resistant to itraconazole and two isolates (11.8 %) were single-resistant to voriconazole. C. albicans isolates that were multi-azoleresistant (fluconazole, itraconazole and/or voriconazole) constituted between 5.9 and 29.4 % of all isolates.
The MIC values used in this study were in accordance with CLSI methodology (CLSI, 2008) ).
Overexpression of the CDR1, CDR2, MDR1 and ERG11 genes
Primer validity for CDR1, CDR2, MDR1, ERG11 and the housekeeping gene 18S rRNA were evaluated by the melting curves and confirmed by electrophoresis on 0.8 % agarose gels. A specific DNA band was detected for all gene amplifications (data not shown). Mean transcript levels of ERG11, CDR1, CDR2 and MDR1 were recorded relative to the susceptible control strain C. albicans ATCC 10231 (Fig. 1) . Compared with control strain C. albicans ATCC 10231, the overexpression of ERG11, CDR1, CDR2 and MDR1 in 17 azole-resistant isolates was 1.7-133.4-, 1.03-2.8-, 1.4-121.1-, 1.02-50.9-fold, respectively. Five isolates showed no overexpression of CDR1 and MDR1. Overexpression of the CDR2 gene was observed in all C. albicans isolates resistant to single fluconazole and also in those resistant to multi-azoles (fluconazole and/or itraconazole, voriconazole). The highest overexpression of ERG11 individually was found in isolates that were resistant to single fluconazole (Table 3 ).
Molecular characteristics of lanosterol 14a-demethylase (CYP51) encoded by the ERG11 gene
The amino acid sequences of the CYP51 proteins of the 17 C. albicans isolates that were resistant to fluconazole were compared with those of C. albicans ATCC 10231, which is sensitive to fluconazole. Overall, six amino acid changes (D116E, D153E, I261V, E266D, V437I, V488I; (Xu et al., 2008; Chau et al., 2004; Goldman et al., 2004) .
Amino acid substitution of CYP51 at E266D was most frequently found in multiresistant C. albicans isolates (fluconazole, itraconazole and voriconazole), while an amino acid Combinations of resistance mechanisms, including overexpression of the CDR1, CDR2, MDR1 and ERG11 genes and an amino acid change in the CYP51 protein in azoleresistant C. albicans, were also analysed in this study (Table 3) . A V437I substitution in the CYP51 protein and overexpression of ERG11 and CDR2 was a predominant combination factor conferring fluconazole resistance to C. albicans. An E266D substitution in the CYP51 protein and overexpression of CDR2 was another predominant combination factor, conferring multi-azole resistance to C. albicans (fluconazole, itraconazole and/or voriconazole). The highest overexpression of ERG11 was found in the resistant isolates without amino acid substitutions in CYP51: more than 100-fold greater than in the susceptible control strain C. albicans ATCC 10231 (Table 3 ). The resistant isolates with amino acid substitutions in CYP51 in at least in two positions showed overexpression in the CDR2 gene that was more than twofold greater than in the susceptible control strain C. albicans ATCC 10231.
DISCUSSION
The major cause of OPC in HIV-infected patients in the Cipto Mangunkusumo Hospital, Jakarta, Indonesia, was C. albicans (85.2 %), while Candida non-albicans, Genetic mechanism of fluconazole resistance including C. dubliniensis, C. guillermondii, C. famata, C. tropicalis and C. parapsilosis, was responsible for 5.5 % of infections. In this study, C. glabrata was not found, although it was considered to be the second most prevalent yeast species after C. albicans. This result indicates that C. glabrata was not frequently the cause of OPC in HIV patients in Jakarta, Indonesia. C. albicans is an opportunistic yeast that has been increasingly implicated in OPC in HIV-infected patients in Indonesia, as reported by Wingeter et al. Both single-and multidrug resistance were found in this study. The most common C. albicans resistance to a single drug was toward fluconazole (17.6 %), which is recommended as a standard treatment for OPC in HIVinfected patients. The majority of the fluconazole-resistant isolates also showed decreased levels of susceptibility to the other azole compounds tested, itraconazole and voriconazole, suggesting that they are multiresistant isolates. This can be explained by the similarity in azole compounds; these are substrates for multidrug efflux transporters that respond to ERG11 mutations (Andes et al., 2006; Song et al., 2004) . Multiple resistance to azole antifungals was mainly associated with specific point mutations in the ERG11 gene (Marichal et al., 1999; Wang et al., 2009; Goldman et al., 2004) , and was also associated with overexpression of the ERG11 gene and efflux pumps encoded by the CDR1, CDR2 and MDR1 genes (Hoot et al., 2008; Oliver et al., 2007) .
Overexpression of ERG11, CDR1, CDR2 and MDR1 was evaluated using the 2 2DDC t method (Chen et al., 2010) , where C t is the mean threshold cycle number from two independent experiments. Data are presented as the fold change in gene expression normalized to the 18S rRNA gene as a control (Chen et al., 2010; Dheda et al., 2004) . Overexpression of the ERG11, CDR1, CDR2 and MDR1 genes was found to be 1.7-133.4, 1.03-2.8, 1.4-121.1 and 1.02-50.9-fold, respectively, compared with C. albicans ATCC 10231, which is sensitive to fluconazole. There were five isolates that showed no overexpression of the CDR1 and MDR1 genes, but amino acid substitutions were also found in these isolates.
The highest overexpression of CDR2 and ERG11 was found in C. albicans resistant to fluconazole isolated from HIVinfected patients in Jakarta, Indonesia. The highest overexpression of ERG11 was found in C. albicans resistant to single fluconazole, whereas the highest overexpression of CDR2 was found in C. albicans multiresistant to fluconazole, itraconazole and/or voriconazole. This result was slightly different from that of Chen et al. (2010) , who reported that the efflux genes, CDR1 and CDR2, are likely to play a more important role in fluconazole resistance.
PCR amplification and sequence analysis of the ERG11 genes showed six different amino acid changes (D116E, D153E, I261V, E266D, V437I and V488I). Amino acid changes occurred commonly in one allele (heterozygous); however, five isolates showed amino acid changes in both alleles (homozygous) -one isolate with D116E, three isolates with E266D and one isolate with V437I. Previous studies reported that ERG11 gene mutations that cause homozygous amino acid changes will increase the potential for resistance (Sanglard & Odds, 2002) . However, in this study, these types of allele mutations did not influence the level of resistance.
In this study, mutations were found to occur in 82 % of all resistant isolates tested, which is higher than the level of 65 % reported by Perea et al. (2001) . Of the six amino acid substitutions, four hotspots of ERG11 gene mutation were found: D116E, E266D, V437I and V488I. These hotspots are located in the three hotspot regions that were reported by Marichal et al. (1999), i.e. aa 105-165, 266-287 and 405-488 . Mutations in the ERG11 gene resulting in the amino acid substitution E266D were found in isolates with multiresistance to fluconazole, itraconazole and voriconazole, while the amino acid substitution V437I was most frequently found in C. albicans resistant to single fluconazole. Based on previous studies in other countries, five substitutions (D116E, D153E, E266D, V437I and V488I) are not directly related to resistance to fluconazole. In this study, only D116E amino acid substitution was found in some sensitive isolates ( Supplementary  Fig. S1 , available in the online Supplementary Material). This shows that genetic polymorphisms of CYP51 are highly permissive to structural changes (Lee et al., 2004; Martínez et al., 2002) .
A novel amino acid substitution (I261V) was found in C. albicans resistant to fluconazole and voriconazole. The amino acid substitution I261V, resulting from the ERG11 gene mutation identified in this study, is probably associated with fluconazole resistance, since the substitution from the large isoleucine to the smaller valine probably hinders the entry of fluconazole.
It appeared that mutations in the ERG11 gene, combined with overexpression of ERG11, CDR1, CDR2 and MDR1, play an important role in the molecular mechanism of C. albicans resistance to single fluconazole or multiresistance to fluconazole, itraconazole and voriconazole. The combination of amino acid substitutions due to mutations in the ERG11 gene and overexpression of CDR2 and ERG11 may occur together in C. albicans isolates resistant to fluconazole. The highest overexpression in the ERG11 gene was found in isolates that had no amino acid substitutions. The highest overexpression was observed in the CDR2 gene, in which amino acid substitutions were associated with C. albicans multiresistance to fluconazole, itraconazole and/or voriconazole.
In summary, a combination of amino acid substitutions due to mutations in the ERG11 gene with overexpression of CDR2 and ERG11 may occur together in C. albicans isolates resistant to single fluconazole and multiresistant to fluconazole, itraconazole and/or voriconazole. The highest overexpression of ERG11 was found in isolates that had no amino acid substitutions. In isolates in which amino acid substitutions were found, the highest overexpression was observed in the CDR2 gene. To the best of our knowledge, studies that combine expression levels of drug-resistancerelated genes and mutations in the ERG11 gene in individual C. albicans strains have not been reported previously. Thus, this study might provide novel and useful information for the therapeutic treatment of candidiasis patients. Moreover, a novel amino acid substitution (I261V) was found in this study; further testing is required to determine whether or not it is associated with fluconazole resistance.
